

1/21

	10	20
hsa-miR-202/1-20	AGAGGUA	-UAGGGCAUGGGAA-
hsa-let-7b/1-22	UGAGGUAGU	AGGUUGUGUGUU
hsa-let-7c/1-22	UGAGGUAGU	AGGUUGUAUGGUU
hsa-let-7a-3/1-22	UGAGGUAGU	AGGUUGUAUAGUU
hsa-let-7a-2/1-22	UGAGGUAGU	AGGUUGUAUAGUU
hsa-let-7a-1/1-22	UGAGGUAGU	AGGUUGUAUAGUU
hsa-let-7e/1-22	UGAGGUAGG	AGGUUGUAUAGUU
hsa-let-7f-1/1-22	UGAGGUAGU	AGAUUGUAUAGUU
hsa-let-7f-2/1-22	UGAGGUAGU	AGAUUGUAUAGUU
hsa-miR-98/1-22	UGAGGUAGU	AAGUUGUAUUGUU
hsa-let-7d/1-22	AGAGGUAGU	AGGUUGCAUAGUU
hsa-let-7g/1-22	UGAGGUAGU	AGUUUGUACAGUU
hsa-let-7i/1-22	UGAGGUAGU	AGUUUGUCUGUU

Consensus
UGAGGUAGUAGGUUGUAUAGUU

FIG. 1A




FIG. 1B

2/21




FIG. 1C




FIG. 1D

3/21




FIG. 2

4/21





FIG. 3

5/21

Data were collected from 1170 patients



Data from 916 patients have been analyzed after quality control

FIG. 4

6/21




FIG. 5

7/21




FIG. 6

8/21

A

miR-202	-0.32	-0.15	-0.34	-0.19	-0.26	-0.1	-0.27	0.15		1
let-7c	0.14	0.08	0.06			0.1		0.3	1	-0.25
let-7b	0.11	0.15			-0.1	0.11		1	0.38	
miR-98	0.37	0.44	0.51	0.4	0.28	0.31	1			-0.42
let-7i	0.15	0.33	0.29	0.28	0.11	1	0.5			-0.35
let-7e	0.33	0.22	0.32	0.24	1	0.34	0.34	0.26		
let-7g	0.34	0.35	0.4	1	0.37	0.53	0.62		0.24	-0.43
let-7f	0.64	0.43	1	0.67	0.34	0.42	0.66			-0.41
let-7d	0.33	1	0.59	0.61	0.35	0.54	0.56	0.26	0.25	-0.39
let-7a	1	0.6	0.57	0.63	0.39	0.47	0.53	0.22	0.32	-0.44

B

miR-202	-0.15		-0.12		-0.1					1
let-7c	0.31	0.13	0.21	0.1		0.12		0.28	1	
let-7b	0.32	0.33	0.29	0.22		0.22	0.16	1		
miR-98	-0.09	0.39	0.28	0.22		0.35	1			
let-7i		0.31	0.23	0.27		1				
let-7e					1					
let-7g	0.11	0.24	0.19	1		0.46	0.45			
let-7f	0.53	0.39	1	0.43			0.42			
let-7d	0.21	1		0.39		0.6				
let-7a	1	0.42		0.46		0.42	0.33			-0.33

C

miR-202	-0.09		-0.13	-0.11	-0.12	-0.1	-0.22			1
let-7c	0.28	0.1	0.19			0.09	0.15	0.26	1	-0.31
let-7b	0.34	0.14	0.2					1	0.33	
miR-98	0.28	0.32	0.43	0.31	0.26	0.24	1			
let-7i	0.13	0.28	0.26	0.22	0.16	1	0.58			
let-7e	0.24	0.21	0.21	0.24	1	0.41	0.45			
let-7g	0.25	0.27	0.3	1	0.52	0.56	0.5			
let-7f	0.49	0.36	1	0.62	0.47	0.5	0.6			
let-7d	0.28	1	0.76	0.63	0.4	0.5	0.63			
let-7a	1	0.65	0.64	0.64	0.49	0.39	0.6		0.34	

D

miR-202					-0.27					1
let-7c	0.43	0.35	0.31					0.41	1	
let-7b	0.31	0.26						1		
miR-98	0.3	0.5	0.48		0.28	0.32	1			
let-7i		0.25	0.28	0.33		1	0.78			-0.61
let-7e	0.3		0.3		1		0.56	0.72		
let-7g	0.35	0.26	0.35	1	0.61					
let-7f	0.52	0.43	1		0.67		0.56			
let-7d	0.38	1	0.61	0.67	0.61					
let-7a	1		0.56		0.56	0.78	0.78			

FIG. 7

10/21




FIG. 8E




FIG. 8F

11/21




FIG. 9A




FIG. 9B

12/21




FIG. 9C




FIG. 9D




FIG. 10


Tumor stage I-II vs. III-IV

FIG. 11A


Low grades (1,2) vs. high grades (3,4)

FIG. 11B


Tumor Residual Disease

FIG. 11C


Primary chemotherapy outcome

FIG. 11D

15/21


Local vs Met recurrence

FIG. 11E


CA125 (220196_at/MUC16)

FIG. 11F


HE4(203892_at/WFDC2)

FIG. 11G


P53 (211300_s_at/TP53)

FIG. 11H


MYC (202431_s_at/MYC)

FIG. 11I

16/21




FIG. 11J




FIG. 12

17/21




FIG. 13A




FIG. 13B

18/21




FIG. 13C




FIG. 13D




FIG. 13E

20/21




FIG. 14

21/21




FIG. 15